Italian region weighs up thalassaemia R&D (research and development) options:
This article was originally published in Clinica
Italy's Marche region has declined an offer by the central government to transform the San Salvatore hospital, Pesaro, into a national centre for research into thalassaemia. During a meeting last week with the ministers of health and of the economy, the regional authorities said they were considering giving foundation status to only part of the hospital, namely the haematology department. The health ministry has expressed regret at the decision, since the centre will miss the opportunity of becoming part of the national and European networks of centres of research excellence. Neither will the centre be entitled to the substantial funding the government has set aside in 2002 for this programme. The Marche region has yet to formally announce its decision to the central government.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.